MODD, GALT, XCUR, PEPG, BSGM Stocks Pop After Hours On Clinical Updates And Strategic Moves

Several biotech stocks experienced significant after-hours trading activity on September 11, 2025, primarily driven by clinical milestones and strategic pivots. Modular Medical (MODD) surged over 30% following the completion of a clinical study for its insulin pump and anticipated October FDA submission, bolstered by insider buying. Concurrently, BioSig Technologies (BSGM) saw a combined increase of over 40% as it rebranded to Streamex Corp. (STEX) and announced a complete strategic pivot from medical devices to real-world asset tokenization via blockchain. Other notable movers included Galectin Therapeutics (GALT), up 14% on continued momentum and anticipation of further data for its MASH cirrhosis candidate, and firms like Exicure (XCUR) and PepGen (PEPG) which saw gains largely attributed to speculative interest amid their respective strategic realignments.

Analysis

The after-hours session on September 11, 2025, revealed significant divergence in the drivers of biotech stock performance, primarily bifurcating between fundamental catalysts and strategic pivots. Modular Medical (MODD) exemplified a catalyst-driven surge, climbing 30.68% after completing a clinical study for its MODD1 insulin pump. This move was reinforced by strong underlying signals, including insider purchases exceeding $500,000 and a pending FDA submission in October 2025, which collectively drove trading volume to 4.5 million shares against a 200,000 average. Similarly, BioSig Technologies (BSGM) executed a complete strategic transformation, rebranding to Streamex Corp. (STEX) and pivoting from medical devices to real-world asset tokenization, resulting in a cumulative gain of over 40%. In contrast, other firms moved on momentum and future promise rather than immediate news. Galectin Therapeutics (GALT) rose 14%, continuing a 360% year-to-date rally on anticipation of new data for its belapectin candidate. Meanwhile, Exicure (XCUR) and PepGen (PEPG) saw gains of 11.11% and 6.67% respectively, attributed to speculative interest following their own strategic realignments; however, these moves are set against challenging fundamentals, including XCUR's widening net loss of $2.6 million and PEPG's recent discontinuation of a key clinical program.

Key Decisions for Investors

• For companies with tangible catalysts like Modular Medical (MODD) and BioSig (BSGM), investors should focus on the execution risk tied to their next milestones, namely MODD's October FDA submission and BSGM's nascent venture into asset tokenization.
• Given Galectin Therapeutics' (GALT) significant 360% year-to-date appreciation and new 52-week high, it may be prudent to monitor for trend exhaustion while awaiting the promised biomarker data, as the current valuation is heavily reliant on future success.
• The speculative gains in Exicure (XCUR) and PepGen (PEPG) should be viewed with caution, as they are not supported by immediate positive fundamentals; positions in these names are highly exposed to the binary outcome of future catalysts, such as PEPG's pivotal DM1 trial data expected in Q4 2025.
• The insider buying at Modular Medical provides a strong positive signal, suggesting executive confidence ahead of a key regulatory submission, a factor that should be weighted heavily in valuation models.